KCT0005014招募中未知
Real-world outcome of crizotinib in ROS1-rearranged non-small cell lung cancer patients
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 0No Limit（—）
- 性别
- All
入选标准
- •1. Patients who were diagnosed as locally advanced or metastatic NSCLC by histologic or cytologic confirmation
- •2. Patients who were diagnosed as histologically or cytologically ROS1 positive adenocarcinoma
- •3. Patients who are to initiate crizotinib treatment for NSCLC
- •But patients who are already under treatment with crizotinib for ROS1-rearranged adenocarcinoma is eligible to the study
- •4. Male or female adult patients aged 19 years old and above
- •5. The patients who provide written informed consent for the study
排除标准
- •1. Patients who have already been treated with cirzotinib(ALK inhibitor)
- •2. Patients whose medical records are not available for review
研究者
相似试验
进行中（未招募）
1 期
Phase II study of crizotinib and Fluvestrant in lobular breast cancer or diffuse gastric cancerEUCTR2017-001680-20-GBRoyal Marsden Hospital58
已完成
2 期
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursLobular Breast CarcinomaGastric CancerTriple Negative Breast CancerCDH1 Gene MutationNCT03620643Royal Marsden NHS Foundation Trust33
进行中（未招募）
1 期
PF-06463922 for crizotinib pretreated ROS1 positive non-small-cell lung cancer: a phase II Trial (PFROST)ROS1 positive non-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001259-34-ITFONDAZIONE RICERCA TRASLAZIONALE (FORT)20
已完成
1 期
A phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and phase I study of this drug for recurrent or refractory neuroblastomaJPRN-UMIN000028075St. Marianna University School of Medicine Hospital National Center for Child Health and Development Nagoya Medical Center Kyushu University Hospital23
Unknown
2 期
PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung CancerCarcinoma, Non-Small-Cell LungNCT03439215Fondazione Ricerca Traslazionale20